Health nut, health specialty, and public health jobs are among the many jobs that the newly created medical marijuana company aims to fill, as its founder and CEO says it hopes to expand to other markets.
The company, Aim, announced Monday that it plans to hire 5,000 people, and expects to add as many as 20,000 jobs in 2019.
Aim’s chief executive, Peter McBride, said that Aim is focusing on growing its supply, expanding its market, and attracting patients who are interested in medical marijuana.
Aim is also targeting the medical marijuana industry to diversify, he said, citing research that showed that the marijuana market is much more diversified than the traditional pharmaceutical sector.
Aim plans to expand into more markets and will begin operations in Canada and Mexico.
Aim will operate a medical marijuana dispensary in Winnipeg, Manitoba, in early 2019, and hopes to open more dispensaries throughout Canada and the United States by 2020.
Aim expects to open up to 30 to 40 dispensaries by 2019.
In an interview with CBC News on Tuesday, McBride said that the company has already spent more than $1.5 million of its $3.4 million investment in the Winnipeg location, which was built in late 2018.
Aim currently has more than 300 employees in the city, McBrides said, and will hire up to 50 more by the end of 2019.
McBride also said that aim has been approached by other medical-related companies interested in growing in Manitoba, and that the two companies have discussed the possibility of collaborating to grow cannabis.
Aim has raised about $300,000 in seed money from private investors, including a group led by Toronto-based entrepreneur Peter Faucher.
Aim also plans to sell cannabis-infused products, Mcbrides said.
Aim said in its announcement that it intends to start with Manitoba, Saskatchewan, Ontario, and Quebec, and is currently recruiting employees in Ontario and Quebec.
Aim had previously raised $100,000 from investors, but was not able to get any further financing.
The medical-cannabis industry has exploded in recent years, as marijuana-specific businesses such as dispensaries, cultivation facilities, and cultivation labs have grown rapidly.
The federal government has approved a number of regulations for medical marijuana producers, including allowing them to cultivate up to 20 plants per dispensary.
The number of recreational pot shops in Canada has grown to more than 1,000, with about 30,000 of them opening each year.
The federal government also allows doctors to recommend that patients be allowed to use cannabis for certain conditions, including cancer and glaucoma.
Aim aims to expand its focus to include people with chronic pain, and McBride has said Aim plans on expanding its products to other conditions.
Aim was founded in late 2014, but has not yet opened a dispensary, McBriensaid.
He said that in 2019 Aim plans in-store testing of its products and expects a store to open in the fall.
McBridersaid that Aim intends to focus on a “high-quality product with a high-value brand.”
Aim will be the first company to use a medical-grade strain of marijuana, and it plans on introducing a strain with “a more focused profile,” McBride said.
The two companies said that they expect to work together to help ensure that patients have access to medical marijuana as the market grows.
Aim has not disclosed how much it has invested in Aim.
Aim did not disclose any of its other investments.
Aim said in a statement that it will continue to be a Canadian-based company.
“We are excited to have the opportunity to partner with Aim to create a better Canadian health-care system,” McBride added.